Vaibhav Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 28 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.70 M
- Revenue Growth -29.26%
- Profit Growth -70.52%
- Ebitda -50.15%
- Net Worth 5.44%
- Total Assets -18.64%
About Vaibhav Drugs
Vaibhav Drugs Private Limited (VDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 04 October 1996 and has a history of 28 years and four months. Its registered office is in Hyderabad-35, Andhra Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company has closed loans amounting to ₹1.70 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Alapati Sridevi and Alapati Rao serve as directors at the Company.
Company Details
- Location
Hyderabad-35, Andhra Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230AP1996PTC025387
- Company No.
025387
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Oct 1996
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Vaibhav Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alapati Sridevi  | Director | 30-May-2012 | Current |
| Alapati Rao | Director | 24-May-2010 | Current |
Financial Performance of Vaibhav Drugs.
Vaibhav Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 29.26% decrease. The company also saw a substantial fall in profitability, with a 70.52% decrease in profit. The company's net worth moved up by a moderate rise of 5.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vaibhav Drugs?
In 2023, Vaibhav Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ridge Formulations Private LimitedAlapati Rao is a mutual person
Charges (Loans)
₹0
₹1.70 M
Charges Breakdown by Lending Institutions
- Deena Bank : 0.17 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Jun 1997 | Deena Bank | ₹1.70 M | Satisfied |
How Many Employees Work at Vaibhav Drugs?
Vaibhav Drugs has a workforce of 17 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vaibhav Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vaibhav Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
